Skip to main content
    I

    Insulet Corporation (PODD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $145.29
    -7.19 (-4.72%)

    Market Cap: $10.58B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insulet Corporation (PODD) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Insulet (PODD) trades at 21.9x trailing earnings and 3.2x sales. Its P/E of 21.9x is below its 5-year median of 79.1x. Its forward P/E is 19.8x. The median P/E across 9 similar companies is 23.8x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 10.6% higher over the next year. Its free cash flow yield is 2.4%.

    MultipleValue
    P/E (trailing)21.9x
    Forward P/E19.8x
    Price to sales3.2x
    Price to book6.4x
    EV/EBITDA15.0x
    Price to FCF41.8x
    EV/FCF43.3x
    PEG1.2
    FCF yield2.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 67.3% below 9.8x and its P/B is 77.9% below 28.9x.

    MultipleCurrent5-year median10-year median
    P/E21.9x79.1xN/A
    P/S3.2x8.9x9.8x
    P/B6.4x16.6x28.9x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 7 of the 10 year ends shown that have a P/E, its P/E ranged from 57.1x in 2025 to 798.8x in 2020. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$284.2457.1x7.4x13.3x
    2024$261.0778.4x9.0x16.0x
    2023$216.9879.8x8.9x20.7x
    2022$294.39303.5x15.7x43.3x
    2021$266.07345.5x16.5x33.4x
    2020$255.63798.8x18.3x27.9x
    2019$171.20611.4x14.2x144.1x
    2018$79.32N/A8.4x22.8x
    2017$69.00N/A8.6x25.3x
    2016$37.68N/A5.9x34.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PODD

    What is PODD's forward P/E ratio?

    Insulet has a forward P/E ratio of 19.8x.

    Is PODD stock overvalued?

    GNG's valuation label for PODD is Undervalued. Its P/E of 21.9x compares with a median of 23.8x across 9 similar companies.

    What is PODD's price to sales ratio?

    Insulet has a price to sales ratio of 3.2x.

    What is Insulet's average P/E ratio over 5 years?

    Insulet's median P/E over the last 5 years is 79.1x, from 60 month-end values through Oct 2026.

    What is PODD's PEG ratio?

    Insulet has a PEG ratio of 1.2.